New trends in the treatment of bone metastasis

Keller, Evan T.; Dai, Jinlu; Escara‐Wilke, June; Hall, Christopher L.; Ignatoski, Kathleen M. Woods; Taichman, Russell S.; Keller, Jill M.

doi:10.1002/jcb.21540

Cited by 16 publications

(9 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, development efforts have increasingly included bone metastases [ 18 ]. Bisphosphonates act by blocking the RANK-RANK ligand interaction [ 19 ]. Second-generation or aminobisphosphonates (ie, zoledronate) may also be useful due to potent RANK inhibition and indirect inhibition of the Ras signaling pathway.…”

Section: Osteoclast Activationmentioning

confidence: 99%

Novel targets with potential therapeutic applications in osteosarcoma

Khanna

2008

Curr Oncol Rep

View full text Add to dashboard Cite

For patients with osteosarcoma, the development of metastases, often to the lungs, is the most common cause of death. Long-term outcomes for patients who present with localized or disseminated disease have largely remained unchanged over the past 20 years. Further improvements in outcome are not likely to come from intensification of cytotoxic chemotherapy; as such, new targets for treatment are needed. A view toward such targets in osteosarcoma may be constructed based on three common clinical features of the disease. These include the origin of osteosarcoma in the bone or primitive mesenchymal cells, the predictable process of metastatic progression characterized by this disease, and the development of metastatic lesions almost exclusively in the lung. It is likely and potentially favorable for some targets to be relevant for more than one process. This review summarizes novel targets under evaluation for the treatment of osteosarcoma based on these three features of the disease.

show abstract

Section: Osteoclast Activationmentioning

confidence: 99%

Novel targets with potential therapeutic applications in osteosarcoma

Khanna

2008

Curr Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Bone metastasis causes consequences, such as bone pain. Bone fractures and nerve compression, seriously affect the patient's quality of life (18,19). Thus, it is urgent to develop accurate predictors and illuminate the mechanisms of PCa distant metastasis.…”

Section: Discussionmentioning

confidence: 99%

Loss of miR-449a-caused PrLZ overexpression promotes prostate cancer metastasis

Chen

Liu

Chen

et al. 2017

International Journal of Oncology

View full text Add to dashboard Cite

Distant metastasis is the worst prognostic factor for PCa patients. It has been reported that miR-449a enhances radiosensitivity of prostate cancer cells, but the function of miR449a in metastasis of prostate cancer is mainly unknown. In the present study, we strove to investigate the function and diagnostic value of miR-449a in metastasis of prostate cancer. qRT-PCR was used to quantify the expression of miR449a and PrLZ in PCa cell lines and tissues. We found that miR449a expression was decreased in PCa cell lines. Moreover, miR-449a was downregulated in PCa tissues, especially in primary lesion tissues of metastatic PCa patients. CCK8, FACS, Transwell and tube formation assay were performed to assess growth and metastasis of PCa cells in vitro. Lentivirus mediated miR-449a overexpression suppressed proliferation of LNcap and PC-3, and miR-449a also significantly inhibited invasion and angiogenesis ability of LNcap and PC-3. IHC showed that PrLZ was upregulated in PCa tissues. Luciferase assay and western blotting verified that miR-449a targeted PrLZ expression. Moreover, PrLZ shRNA also significantly suppressed proliferation and metastasis of LNcap and PC-3. In addition, western blotting revealed that miR-449a overexpression and PrLZ shRNA all remarkably inhibited the stemness features in LNcap and PC-3. Furthermore, BALB/c nude mouse subcutaneous xenograft model was uesd to verify the function of miR-449a and PrLZ. Our results showed that miR-449a and PrLZ shRNA significantly suppressed PC-3 tumorigenesis and metastasis in vivo. Our studies suggested that miR-449a decreased in malignant process of PCa and was accompanied by excess expression of PrLZ. The loss of miR-449a caused PrLZ overexpression regulated prostate cancer progression and metastasis via regulating the stemness features of prostate cancer cells. The diagnostic value of miR-449a as a distant metastasis predictor of PCa needs further investigation.

show abstract

“…Once the tumor has developed bone metastases, the disease in most cases is incurable. However, surgical resection of these metastases and stabilization of pathologic fractures are generally considered a valuable palliative treatment [8]. The adjuvant chemotherapy is effective to slow down tumor growth and metastasis outgrowth.…”

Section: Introductionmentioning

confidence: 99%